556 related articles for article (PubMed ID: 28843359)
1. Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.
Arulananda S; Do H; Musafer A; Mitchell P; Dobrovic A; John T
J Thorac Oncol; 2017 Nov; 12(11):1728-1732. PubMed ID: 28843359
[TBL] [Abstract][Full Text] [Related]
2. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB
J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341
[TBL] [Abstract][Full Text] [Related]
3. Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
Ariyasu R; Uchibori K; Sasaki T; Tsukahara M; Kiyotani K; Yoshida R; Ono Y; Kitazono S; Ninomiya H; Ishikawa Y; Mizukami Y; Yanagitani N; Fujita N; Nishio M; Katayama R
Cancer Sci; 2021 Jun; 112(6):2371-2380. PubMed ID: 33686722
[TBL] [Abstract][Full Text] [Related]
4. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
Wang LS; Chen SQ; Zhong X; Jiao XD; Liu K; Qin BD; Wu Y; Ling Y; Duan XP; Zang YS
Anticancer Drugs; 2023 Nov; 34(10):1146-1150. PubMed ID: 36728908
[TBL] [Abstract][Full Text] [Related]
5. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
[TBL] [Abstract][Full Text] [Related]
6. Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.
Chen ZW; Lin G; Shih HJ; Wu CE
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614045
[TBL] [Abstract][Full Text] [Related]
7. Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
Proto C; Lo Russo G; Corrao G; Ganzinelli M; Facchinetti F; Minari R; Tiseo M; Garassino MC
Tumori; 2017 Jul; 103(4):325-337. PubMed ID: 28708233
[TBL] [Abstract][Full Text] [Related]
8. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625
[TBL] [Abstract][Full Text] [Related]
10. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
12. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.
Wang S; Tsui ST; Liu C; Song Y; Liu D
J Hematol Oncol; 2016 Jul; 9(1):59. PubMed ID: 27448564
[TBL] [Abstract][Full Text] [Related]
13. Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance.
Wang Z; Yang JJ; Huang J; Ye JY; Zhang XC; Tu HY; Han-Zhang H; Wu YL
J Thorac Oncol; 2017 Nov; 12(11):1723-1727. PubMed ID: 28662863
[TBL] [Abstract][Full Text] [Related]
14. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.
Yang Z; Yang N; Ou Q; Xiang Y; Jiang T; Wu X; Bao H; Tong X; Wang X; Shao YW; Liu Y; Wang Y; Zhou C
Clin Cancer Res; 2018 Jul; 24(13):3097-3107. PubMed ID: 29506987
[No Abstract] [Full Text] [Related]
15. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
[TBL] [Abstract][Full Text] [Related]
16. Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients.
Yang Y; Xu H; Ma L; Yang L; Yang G; Zhang S; Ai X; Zhang S; Wang Y
Cancer Med; 2021 Dec; 10(23):8328-8337. PubMed ID: 34612594
[TBL] [Abstract][Full Text] [Related]
17. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.
Knebel FH; Bettoni F; Shimada AK; Cruz M; Alessi JV; Negrão MV; Reis LFL; Katz A; Camargo AA
Lung Cancer; 2017 Jun; 108():238-241. PubMed ID: 28625643
[TBL] [Abstract][Full Text] [Related]
18. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C
Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559
[TBL] [Abstract][Full Text] [Related]
19. Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells.
Yonesaka K; Kobayashi Y; Hayashi H; Chiba Y; Mitsudomi T; Nakagawa K
Oncol Rep; 2019 Feb; 41(2):1059-1066. PubMed ID: 30483795
[TBL] [Abstract][Full Text] [Related]
20. Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.
Uchibori K; Inase N; Nishio M; Fujita N; Katayama R
J Thorac Oncol; 2018 Jul; 13(7):915-925. PubMed ID: 29702287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
